Similar to pan-HDAC inhibitors approved for the treatment of hematological cancers, specific HDAC6 inhibitors showed anti-cancer properties in various cancer types such as multiple myeloma [183], chronic lymphocytic leukemia [114], and acute myeloid leukemia [184]. Here, HDAC6 is linked to acute myeloid leukemia.